Profil
John Hayslip currently works at Verastem, Inc., as Chief Medical Officer from 2024.
Dr. Hayslip also formerly worked at The Markey Cancer Center Foundation, as Director-Clinical Research & Data Management, Nektar Therapeutics, as Vice President-Clinical Development, and I-Mab, as Chief Medical Officer from 2022 to 2024.
Dr. Hayslip received his graduate degree from The Medical University of South Carolina and doctorate degree from Northeast Ohio Medical University.
Aktive Positionen von John Hayslip
| Unternehmen | Position | Beginn |
|---|---|---|
| VERASTEM, INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.04.2024 |
Ehemalige bekannte Positionen von John Hayslip
| Unternehmen | Position | Ende |
|---|---|---|
| NOVABRIDGE BIOSCIENCES | Technik-/Wissenschafts-/F&E-Leiter | 15.04.2024 |
The Markey Cancer Center Foundation | Corporate Officer/Principal | - |
| NEKTAR THERAPEUTICS | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von John Hayslip
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Nektar Therapeutics
Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Medical University of South Carolina
Medical University of South Carolina Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Markey Cancer Center Foundation | |
Verastem, Inc.
Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Northeast Ohio Medical University
Northeast Ohio Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
I-Mab
I-Mab Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for cancer and autoimmune diseases | Health Technology |
















